A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...
Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...
Please provide your email address to receive an email when new articles are posted on . One journal reviewer told Donald P. McDonnell, PhD, the research should be “banned from the literature.” A ...
4don MSN
Easy-to-use tool can identify high- and low-risk metastatic prostate cancer patients earlier
A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...
Precision medicine in prostate cancer utilizes genetic testing to identify patients for PARP inhibitor treatment, enhancing personalized care. Genetic testing, including germline and somatic, is ...
A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback